Further analysis of cancer and adjacent normal tissues using the GTEx database revealed significant differences in FZD2 expression in GBM, lower-grade glioma (LGG), lung adenocarcinoma (LUAD), testicular germ cell tumors (TGCT), skin cutaneous melanoma (SKCM), ovarian serous cystadenocarcinoma (OV), pancreatic adenocarcinoma (PAAD), and other cancers. This evidence concerns the gene FZD2 and glioblastoma.